Clinical trials


Durvalumab (MEDI4736) After chemoRadioTherapy for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients More information	Nivolumab and Ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma – a phase II randomised clinical and translational trial More information
	NorPACT-2
Immunotherapy combined with extensive radiotherapy for the treatment of stage IV non-small cell lung cancer (COM-IT-2) – a phase II randomised clinical and translational trial More information	Norwegian Pancreatic Cancer Trial (NorPACT)-2: Liquid biopsies and blood-based biomarkers (https://www.ous-research.no/ pancreaticcancer)

Scroll to top

Recent publications

Silwal-Pandit L, Stålberg SM, Johansson HJ, Mermelekas G, Lothe IMB, Skrede ML, Dalsgaard AM, Nebdal DJH, Helland Å, Lingjærde OC, Labori KJ, Skålhegg BS, Lehtiö J, Kure EH (2022)
Proteome Analysis of Pancreatic Tumors Implicates Extracellular Matrix in Patient Outcome
Cancer Res Commun, 2 (6), 434-446
DOI 10.1158/2767-9764.CRC-21-0100, PubMed 36923555

Ottesen JA, Yi D, Tong E, Iv M, Latysheva A, Saxhaug C, Jacobsen KD, Helland Å, Emblem KE, Rubin DL, Bjørnerud A, Zaharchuk G, Grøvik E (2023)
2.5D and 3D segmentation of brain metastases with deep learning on multinational MRI data
Front Neuroinform, 16, 1056068
DOI 10.3389/fninf.2022.1056068, PubMed 36743439

Skoie IM, Skogås JG, Langø T, Myhr KM, Myhre PL, Goll R, Fretland SØ, Helland Å (2023)
New centres to carry out more clinical trials in Norway
Tidsskr Nor Laegeforen, 143 (2)
DOI 10.4045/tidsskr.22.0722, PubMed 36718905

More publications

NorPACT-2